Non-Small Cell Lung Carcinoma Advanced | TNM clinical staging | Neoplasm Metastasis Recurrence Local Inoperable Evidence of
Item
histologically or cytologically confirmed advanced stage iv nsclc with evidence of inoperable local recurrence or metastasis
boolean
C0007131 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C3258246 (UMLS CUI [2])
C0027627 (UMLS CUI [3,1])
C2825055 (UMLS CUI [3,2])
C0205276 (UMLS CUI [3,3])
C0205187 (UMLS CUI [3,4])
C0332120 (UMLS CUI [3,5])
Pregnancy | Breast Feeding | Serum pregnancy test negative | Childbearing Potential | Contraceptive methods
Item
if female, non-pregnant and not lactating, with a negative serum pregnancy test, and either not of child-bearing potential or practicing an approved contraception method
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0430061 (UMLS CUI [3])
C3831118 (UMLS CUI [4])
C0700589 (UMLS CUI [5])
Age
Item
eighteen years of age or older
boolean
C0001779 (UMLS CUI [1])
Malignant Neoplasms
Item
no other current active malignancy
boolean
C0006826 (UMLS CUI [1])
Measurable Disease | Radiography
Item
measurable disease (defined by recist criteria) documented radiographically
boolean
C1513041 (UMLS CUI [1])
C0034571 (UMLS CUI [2])
Prior Chemotherapy Neoplasm Metastasis | Therapeutic radiology procedure Completed Bone Marrow Area Major | Epidermal Growth Factor Targeted Therapy
Item
patient must have received no prior chemotherapies for the treatment of metastatic disease. radiation therapy to a major bone marrow-containing area must have been completed 3 or more weeks prior to study entry. prior treatment with egf-targeted therapies is permitted.
boolean
C1514457 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C1522449 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
C0005953 (UMLS CUI [2,3])
C0205146 (UMLS CUI [2,4])
C0205164 (UMLS CUI [2,5])
C0242275 (UMLS CUI [3,1])
C2985566 (UMLS CUI [3,2])
Absolute neutrophil count | Platelet Count measurement | Hemoglobin
Item
if, at baseline, patient has anc greater than or equal to 1.5 x 109 cells/l; platelets greater than or equal to 100 x 109 cells/l and hgb greater than or equal to 9 g/dl
boolean
C0948762 (UMLS CUI [1])
C0032181 (UMLS CUI [2])
C0019046 (UMLS CUI [3])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Bilirubin total normal | Creatinine measurement, serum | Alkaline phosphatase measurement | Alkaline phosphatase raised Related Secondary malignant neoplasm of bone | Secondary malignant neoplasm of liver Evidence Radiologic
Item
if, at baseline, patient has ast and alt of less than or equal to 2.5 x the upper limit of normal range; a total bilirubin normal; creatinine levels less than or equal to 1.5 mg/dl and alkaline phosphatase levels less than or equal to 2.5 x the upper limit of normal range (unless alkaline phosphatase elevation is felt to be related to bone metastases and there is no radiologic evidence of hepatic metastasis)
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C0860928 (UMLS CUI [3])
C0201976 (UMLS CUI [4])
C0201850 (UMLS CUI [5])
C0151849 (UMLS CUI [6,1])
C0439849 (UMLS CUI [6,2])
C0153690 (UMLS CUI [6,3])
C0494165 (UMLS CUI [7,1])
C3887511 (UMLS CUI [7,2])
C0205483 (UMLS CUI [7,3])
Continuance of life Expected
Item
expected survival of greater than 12 weeks
boolean
C0038952 (UMLS CUI [1,1])
C1517001 (UMLS CUI [1,2])
ECOG performance status | Karnofsky Performance Status
Item
ecog performance status 0-1 (karnofsky > 70)
boolean
C1520224 (UMLS CUI [1])
C0206065 (UMLS CUI [2])
Informed Consent | Informed Consent Patient Representative | Informed Consent Legal Guardian
Item
patient or his/her legally authorized representative or guardian has been informed about the nature of the study, and has agreed to participate in the study, and signed the informed consent form prior to participation in any study-related activities.
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
C0021430 (UMLS CUI [3,1])
C0023226 (UMLS CUI [3,2])